Literature DB >> 18303834

Reproducibility of mass spectrometry based protein profiles for diagnosis of breast cancer across clinical studies: a systematic review.

Anne K Callesen1, Werner Vach, Per E Jørgensen, Søren Cold, Ole Mogensen, Torben A Kruse, Ole N Jensen, Jonna S Madsen.   

Abstract

Serum protein profiling by mass spectrometry has achieved attention as a promising technology in oncoproteomics. We performed a systematic review of published reports on protein profiling as a diagnostic tool for breast cancer. The MEDLINE, EMBASE, and COCHRANE databases were searched for original studies reporting discriminatory protein peaks for breast cancer as either protein identity or as m/ z values in the period from January 1995 to October 2006. To address the important aspect of reproducibility of mass spectrometry data across different clinical studies, we compared the published lists of potential discriminatory peaks with those peaks detected in an original MALDI MS protein profiling study performed by our own research group. A total of 20 protein/peptide profiling studies were eligible for inclusion in the systematic review. Only 3 reports included information on protein identity. Although the studies revealed a considerable heterogeneity in relation to experimental design, biological variation, preanalytical conditions, methods of computational data analysis, and analytical reproducibility of profiles, we found that 45% of peaks previously reported to correlate with breast cancer were also detected in our experimental study. Furthermore, 25% of these redetected peaks also showed a significant difference between cases and controls in our study. Thus, despite known problems related to reproducibility, we were able to demonstrate overlap in peaks between clinical studies indicating some convergence toward a set of common discriminating, reproducible peaks for breast cancer. These peaks should be further characterized for identification of the protein identity and validated as biomarkers for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303834     DOI: 10.1021/pr800115f

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  20 in total

1.  Quality control based on isotopic distributions for high-throughput MALDI-TOF and MALDI-FTICR serum peptide profiling.

Authors:  Simone Nicolardi; Magnus Palmblad; Hans Dalebout; Marco Bladergroen; Rob A E M Tollenaar; André M Deelder; Yuri E M van der Burgt
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-12       Impact factor: 3.109

2.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

3.  Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.

Authors:  Alicia D Powers; Sean P Palecek
Journal:  J Healthc Eng       Date:  2012-12       Impact factor: 2.682

Review 4.  Breast cancer proteomics: a review for clinicians.

Authors:  E R C G N Galvão; L M S Martins; J O Ibiapina; H M Andrade; S J H Monte
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-05       Impact factor: 4.553

5.  Mass spectrometric characterization of protein structure details refines the proteome signature for invasive ductal breast carcinoma.

Authors:  Claudia Röwer; Cornelia Koy; Michael Hecker; Toralf Reimer; Bernd Gerber; Hans-Jürgen Thiesen; Michael O Glocker
Journal:  J Am Soc Mass Spectrom       Date:  2011-02-08       Impact factor: 3.109

6.  Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.

Authors:  Monika Pietrowska; Lukasz Marczak; Joanna Polanska; Katarzyna Behrendt; Elzbieta Nowicka; Anna Walaszczyk; Aleksandra Chmura; Regina Deja; Maciej Stobiecki; Andrzej Polanski; Rafal Tarnawski; Piotr Widlak
Journal:  J Transl Med       Date:  2009-07-13       Impact factor: 5.531

Review 7.  Challenges, current status and future perspectives of proteomics in improving understanding, diagnosis and treatment of vascular disease.

Authors:  J V Moxon; M P Padula; B R Herbert; J Golledge
Journal:  Eur J Vasc Endovasc Surg       Date:  2009-07-09       Impact factor: 7.069

Review 8.  Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.

Authors:  Ken Herrmann; Axel Walch; Benjamin Balluff; Marc Tänzer; Heinz Höfler; Bernd J Krause; Markus Schwaiger; Helmut Friess; Roland M Schmid; Matthias P A Ebert
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-03

9.  Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.

Authors:  Berit Velstra; Yuri E M van der Burgt; Bart J Mertens; Wilma E Mesker; André M Deelder; Rob A E M Tollenaar
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-05       Impact factor: 4.553

10.  Sensitive and specific peak detection for SELDI-TOF mass spectrometry using a wavelet/neural-network based approach.

Authors:  Vincent A Emanuele; Gitika Panicker; Brian M Gurbaxani; Jin-Mann S Lin; Elizabeth R Unger
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.